Key result
Testing for antibodies against individual ribosomal proteins, particularly anti-Rib-P0, provides additional diagnostic benefit in SLE, identifying 39.6% of patients who tested negative for the standard anti-Rib-P antibody.
Why the study?
Anti-ribosomal P antibody routinely targets the common epitope of ribosomal proteins P0, P1, and P2; this study investigated whether testing antibodies against individual ribosomal proteins is required for optimal diagnostic benefit in SLE.
Does testing antibodies against individual ribosomal proteins improve diagnostic benefit compared to testing the common epitope in patients with SLE?
Cross-Sectional (n=104)
No
Does testing antibodies against individual ribosomal proteins improve diagnostic benefit compared to testing the common epitope in patients with SLE?
Absolute Event Rate: 45.1% vs 35.4%
Testing for individual ribosomal proteins (P0, P1, P2) provides additional diagnostic value in SLE patients who test negative for the common anti-Rib-P antibody.
No takes yet. Share an insight, caveat, or question.
Standard anti-Rib-P testing may miss individual anti-P0/P1/P2 antibodies in SLE; leaves open whether targeted testing improves diagnostic yield.
Shi et al. (2020) conducted a cross-sectional in Systemic lupus erythematosus (n=104). Antibodies against individual ribosomal proteins (P0, P1, P2) vs. Anti-Rib-P antibody (common epitope) was evaluated on Sensitivity of antibodies at 99% specificity. Testing for antibodies against individual ribosomal proteins, particularly anti-Rib-P0, provides additional diagnostic benefit in SLE, identifying 39.6% of patients who tested negative for the standard anti-Rib-P antibody.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: